Patient characteristics (N = 156)
| Median age, y (range) | 27 (4-58) |
| BMT type (%) | |
| Allogeneic | 129 (82.7) |
| Autologous/syngeneic | 25/02 (17.3) |
| Underlying diseases (%) | |
| CML | 47 (30.1) |
| SAA | 43 (27.5) |
| AML | 20 (12.8) |
| NHL | 17 (10.9) |
| ALL | 11 (7.1) |
| Other | 18 (11.5) |
| Measles vaccination after BMT | 34 (21.8) |
| Acute GVHD*: grade ≥ 2 (%) | 10/15 (66.6) |
| Chronic GVHD†: extensive or limited (%) | 28/114 (24.5) |
| Immunosuppressive drugs‡ (%) | 34/129 (26.4) |
| Median age, y (range) | 27 (4-58) |
| BMT type (%) | |
| Allogeneic | 129 (82.7) |
| Autologous/syngeneic | 25/02 (17.3) |
| Underlying diseases (%) | |
| CML | 47 (30.1) |
| SAA | 43 (27.5) |
| AML | 20 (12.8) |
| NHL | 17 (10.9) |
| ALL | 11 (7.1) |
| Other | 18 (11.5) |
| Measles vaccination after BMT | 34 (21.8) |
| Acute GVHD*: grade ≥ 2 (%) | 10/15 (66.6) |
| Chronic GVHD†: extensive or limited (%) | 28/114 (24.5) |
| Immunosuppressive drugs‡ (%) | 34/129 (26.4) |
CML indicates chronic myelogenous leukemia; SAA, severe aplastic anemia; AML, acute myelogenous leukemia; NHL, non-Hodgkin lymphoma; and ALL, acute lymphoid leukemia.
In 15 allogeneic recipients within the first 100 days after BMT at the evaluation.
In 114 patients after day +100.
Patients on immunosuppression at the time of evaluation.